NL301037I2 - Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan - Google Patents
Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan Download PDFInfo
- Publication number
- NL301037I2 NL301037I2 NL301037C NL301037C NL301037I2 NL 301037 I2 NL301037 I2 NL 301037I2 NL 301037 C NL301037 C NL 301037C NL 301037 C NL301037 C NL 301037C NL 301037 I2 NL301037 I2 NL 301037I2
- Authority
- NL
- Netherlands
- Prior art keywords
- solamphetol
- pharmaceutically acceptable
- salt
- acceptable salt
- hydrochloride salt
- Prior art date
Links
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68863805P | 2005-06-08 | 2005-06-08 | |
| PCT/US2006/022407 WO2006133393A1 (en) | 2005-06-08 | 2006-06-07 | Treatment of sleep-wake disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301037I1 NL301037I1 (enExample) | 2020-04-01 |
| NL301037I2 true NL301037I2 (nl) | 2020-05-12 |
Family
ID=37085728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301037C NL301037I2 (nl) | 2005-06-08 | 2020-03-30 | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US8440715B2 (enExample) |
| EP (1) | EP1890684B1 (enExample) |
| JP (1) | JP5024635B2 (enExample) |
| KR (1) | KR101335941B1 (enExample) |
| CN (1) | CN101217949B (enExample) |
| AU (1) | AU2006254899B2 (enExample) |
| BE (1) | BE2020C004I2 (enExample) |
| BR (1) | BRPI0613697A2 (enExample) |
| CA (1) | CA2611713C (enExample) |
| DK (1) | DK1890684T3 (enExample) |
| ES (1) | ES2435403T3 (enExample) |
| FR (1) | FR20C1014I2 (enExample) |
| NL (1) | NL301037I2 (enExample) |
| PL (1) | PL1890684T3 (enExample) |
| RU (1) | RU2417077C2 (enExample) |
| TW (2) | TW201328689A (enExample) |
| WO (1) | WO2006133393A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| US8552060B2 (en) * | 2005-06-22 | 2013-10-08 | Sk Biopharmaceuticals Co., Ltd. | Methods for treatment of sexual dysfunction |
| AU2010270971B2 (en) * | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US8623913B2 (en) * | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) * | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| RU2019114940A (ru) * | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| DK3021838T3 (da) | 2013-07-18 | 2020-08-24 | Jazz Pharmaceuticals Ireland Ltd | Behandling af fedme |
| TWI655179B (zh) | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| WO2016061488A1 (en) | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
| JP6466792B2 (ja) * | 2015-07-03 | 2019-02-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
| TWI637765B (zh) * | 2016-05-10 | 2018-10-11 | 台灣共振波研發股份有限公司 | Soothing device for attention deficit hyperactivity disorder |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| CN121202730A (zh) | 2016-09-06 | 2025-12-26 | 爱尔兰贾兹制药有限公司 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
| KR20200016889A (ko) | 2017-06-02 | 2020-02-17 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
| SG11202000817SA (en) * | 2017-07-31 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Carbamoyl phenylalaninol analogs and uses thereof |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US11033214B1 (en) * | 2020-05-19 | 2021-06-15 | United Arab Emirates University | Wearable eye tracking system |
| KR102390194B1 (ko) | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| WO2024102718A1 (en) * | 2022-11-07 | 2024-05-16 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| US20260199282A1 (en) * | 2022-11-30 | 2026-07-16 | Axsome Therapeutics, Inc. | Methods and compositions for improving driving performance |
| CN121620365A (zh) | 2023-06-29 | 2026-03-06 | 艾克萨姆治疗股份有限公司 | 向哺乳期妇女施用索安非托的方法 |
| AU2025216819A1 (en) * | 2024-01-29 | 2026-07-09 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
| WO2026125068A1 (en) | 2024-12-10 | 2026-06-18 | Noucor Health, S.A. | Process to obtain solriamfetol hydrochloride |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2939660A1 (de) * | 1979-09-29 | 1981-04-16 | Basf Ag, 6700 Ludwigshafen | Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| NZ314570A (en) | 1993-06-10 | 2000-11-24 | Lilly Co Eli | Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) * | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) * | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2240060C (en) * | 1996-10-10 | 2007-07-17 | Sk Corporation | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| HUP0303243A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating bipolar disorder |
| MXPA03007720A (es) * | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad. |
| RS50676B (sr) * | 2001-02-27 | 2010-06-30 | Ortho-Mcneil Pharmaceutical Inc. | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| US8552060B2 (en) | 2005-06-22 | 2013-10-08 | Sk Biopharmaceuticals Co., Ltd. | Methods for treatment of sexual dysfunction |
| EP1928451B1 (en) | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| AU2007313017A1 (en) | 2006-10-13 | 2008-04-24 | Janssen Pharmaceutica, N.V. | Phenylalkylamino carbamate compositions |
| AU2010270971B2 (en) | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| KR102005483B1 (ko) | 2012-10-19 | 2019-07-31 | 삼성디스플레이 주식회사 | 박막 트랜지스터 기판 및 그의 수리 방법 |
| RU2019114940A (ru) * | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
-
2006
- 2006-06-07 PL PL06772647T patent/PL1890684T3/pl unknown
- 2006-06-07 WO PCT/US2006/022407 patent/WO2006133393A1/en not_active Ceased
- 2006-06-07 EP EP06772647.1A patent/EP1890684B1/en not_active Expired - Lifetime
- 2006-06-07 ES ES06772647T patent/ES2435403T3/es not_active Expired - Lifetime
- 2006-06-07 DK DK06772647.1T patent/DK1890684T3/da active
- 2006-06-07 AU AU2006254899A patent/AU2006254899B2/en not_active Expired
- 2006-06-07 RU RU2008100019/15A patent/RU2417077C2/ru active
- 2006-06-07 TW TW101130937A patent/TW201328689A/zh unknown
- 2006-06-07 TW TW095120134A patent/TWI419681B/zh not_active IP Right Cessation
- 2006-06-07 KR KR1020087000522A patent/KR101335941B1/ko not_active Expired - Lifetime
- 2006-06-07 CA CA2611713A patent/CA2611713C/en not_active Expired - Fee Related
- 2006-06-07 CN CN2006800253545A patent/CN101217949B/zh not_active Expired - Lifetime
- 2006-06-07 JP JP2008515949A patent/JP5024635B2/ja not_active Expired - Lifetime
- 2006-06-07 US US11/921,995 patent/US8440715B2/en active Active
- 2006-06-07 BR BRPI0613697-4A patent/BRPI0613697A2/pt not_active Application Discontinuation
-
2013
- 2013-01-23 US US13/747,508 patent/US8877806B2/en not_active Expired - Lifetime
-
2014
- 2014-08-06 US US14/452,816 patent/US9604917B2/en not_active Expired - Lifetime
-
2017
- 2017-02-15 US US15/433,660 patent/US10351517B2/en not_active Expired - Lifetime
-
2019
- 2019-05-23 US US16/420,834 patent/US20190367448A1/en not_active Abandoned
-
2020
- 2020-03-30 NL NL301037C patent/NL301037I2/nl unknown
- 2020-04-16 FR FR20C1014C patent/FR20C1014I2/fr active Active
- 2020-05-07 BE BE2020C004C patent/BE2020C004I2/nl unknown
- 2020-09-28 US US17/034,564 patent/US11753368B2/en not_active Expired - Lifetime
-
2023
- 2023-08-03 US US18/364,689 patent/US12209059B2/en not_active Expired - Lifetime
-
2024
- 2024-12-13 US US18/979,843 patent/US20250109099A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2024010I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
| NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
| NO2023047I1 (no) | Cedazuridine, or a pharmaceutically acceptable salt thereof | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2022057I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| FIC20240039I1 (fi) | Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301202I1 (nl) | Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline | |
| NL301042I1 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301104I2 (nl) | Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat. | |
| NL301004I2 (nl) | Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301065I2 (nl) | Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride | |
| NL301003I2 (nl) | Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300993I2 (nl) | Apalutamide of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300865I1 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
| NL301177I2 (nl) | tecovirimat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301304I2 (nl) | aprocitentan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301020I2 (nl) | Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat | |
| NO2022022I1 (no) | Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate | |
| NL300990I1 (nl) | Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan | |
| NL300996I1 (nl) | Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout | |
| NL300913I2 (nl) | Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride | |
| NL300886I2 (nl) | baricitinib, of een farmaceutisch aanvaardbaar zout daarvan | |
| NL300703I2 (nl) | Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium. |